How AI is Propelling Radiology & Medical Imaging Capabilities
Bio Spectrum|BioSpectrum India Nov 2024
Medical imaging has been used extensively for early diagnosis of various diseases. Be it computed tomography (CT), mammography, ultrasonography, magnetic resonance imaging (MRI), and nuclear medicine tests, radiologists and pathologists have relied on these images to analyse the condition of patients. However, most of the analysis has been manual, heavily depending on the skill sets of the radiologists or pathologists to identify anomalies in the images. The challenge has been the enormous volumes of patient samples to be analysed and the limited number of radiologists or pathologists. Let's take an in-depth look at the impact and possibilities of AI and new applications in the Indian context.
Suraj Nair
How AI is Propelling Radiology & Medical Imaging Capabilities

In India, there is only one radiologist for every one lakh patients, which translates to one radiologist for every 100 scans performed each day. There is a severe shortage of radiologists in tier 2 and 3 cities as well. As the number of scans keeps rising and new high-resolution imaging technologies enter the market, it has become highly imperative to develop faster analytical techniques to assist pathologists and radiologists.

Enter AI, ML

Artificial intelligence (AI), using machine learning (ML) and deep learning (DL) algorithms has provided interventions in this direction. Machine learning and deep learning algorithms have been used for the past decade to interpret and analyse medical images and aid radiologists and pathologists in screening and diagnosis. Today AI has extended its capability to the entire radiology world, which includes digitising the devices, aiding in diagnosis and finally collating all the data and information into a digital assistant. Image analysis can be broken down into computer-aided detection, diagnosis, and image segmentation. Computer-aided detection and diagnosis involves the use of AI algorithms to analyse medical images and detect abnormalities and diseases.

On the other hand, image segmentation uses AI algorithms to identify and label various parts of a medical image as organs, blood vessels, or tumours. This can help radiologists locate abnormalities and design surgeries more accurately. For example, around 3.5 billion chest X-rays are performed annually worldwide, which require timely and accurate interpretation. AI solutions categorise X-rays based on suspicions of diseases which can be prioritised by radiologists for faster diagnoses boosting efficiency by 30-50 per cent.

This story is from the BioSpectrum India Nov 2024 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the BioSpectrum India Nov 2024 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIO SPECTRUMView All
Amit Agrawal steps in as new Pharmaceuticals Secretary
Bio Spectrum

Amit Agrawal steps in as new Pharmaceuticals Secretary

Amit Agrawal, the Chief Executive Officer (CEO) of the Unique Identification Authority of India (UIDAI), has been appointed as the new Secretary of the Department of Pharmaceuticals, Government of India.

time-read
1 min  |
BioSpectrum Indian Feb 2025
IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes
Bio Spectrum

IIT-B joins hands with Tohoku University to offer MTech, PhD dual degree programmes

The Indian Institute of Technology, Bombay (IIT-B) has entered into a Memorandum of Understanding (MoU) with Japan's Tohoku University to launch the IIT Bombay-Tohoku University Joint Academic & Research Programme.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Innovative injectable hydrogel to offer targeted breast cancer therapy
Bio Spectrum

Innovative injectable hydrogel to offer targeted breast cancer therapy

In a multi-institutional research led by researchers from Indian Institute of Technology Guwahati (IIT-G) and Bose Institute Kolkata, an advanced injectable hydrogel has been developed for localised cancer treatment.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation
Bio Spectrum

Bio-Techne, Waters ink co-marketing agreement for biotherapeutic characterisation

American life sciences company Bio-Techne Corporation, a leader in automated platforms for biotherapeutic characterisation, has announced a co-marketing and co-promotion agreement with Waters Corporation aimed at expanding the reach of advanced biotherapeutic characterisation and development processes.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease
Bio Spectrum

Nano-formulation of darkness hormone to serve as therapeutic solution for Parkinson's disease

Scientists from Institute of Nano Science and Technology (INST) Mohali have proved that nano-formulation of Melatonin, the hormone produced by the brain in response to darkness, showed improved antioxidative and neuroprotective properties and could be a potential therapeutic solution for Parkinson's disease (PD).

time-read
1 min  |
BioSpectrum Indian Feb 2025
"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"
Bio Spectrum

"Govt should facilitate low-interest loans or VC funding specifically for biopharma startups & small enterprises"

\"In a recent development, Nagpur-based biotech company GeNext Genomics (GNG) has joined -hands with Merck Life Science to support the Indian biotech system, particularly in the area of biomanufacturing, which is garnering more attention after the approval of the BioE3 policy.Supriya Kashikar, Founder & Chief Executive Officer, GeNext Genomics shares her views with BioSpectrum on the growth of biomanufacturing sector in India, and how the company plans to play a relevant role in this aspect.

time-read
4 mins  |
BioSpectrum Indian Feb 2025
Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman
Bio Spectrum

Redcliffe Labs reinforces strategic leadership as Aditya Kandoi steps into CEO role, Dheeraj Jain as Chairman

Redcliffe Labs, a purpose-driven pan-India omnichannel diagnostics service provider, has announced a strategic leadership transition.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Zyla Health on-boards Rohit Boda as Advisor
Bio Spectrum

Zyla Health on-boards Rohit Boda as Advisor

Gurugram-based Zyla Health, a care management platform, has announced the onboarding of renowned industry leader, Rohit Boda, to the Board of Advisors.

time-read
1 min  |
BioSpectrum Indian Feb 2025
Claypond Capital appoints Shravan Subramanyam to lead medtech platform
Bio Spectrum

Claypond Capital appoints Shravan Subramanyam to lead medtech platform

Claypond Capital, the family investment office of Dr Ranjan Pai, has announced the appointment of Dr Shravan Subramanyam as the head of its medical technology platform.

time-read
1 min  |
BioSpectrum Indian Feb 2025
How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry
Bio Spectrum

How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry

India's life sciences sector is undergoing a major transformation, led by the expansion of Global Capability Centres GCCs). These centres, which serve as strategic hubs for multinational companies in pharmaceuticals, biotechnology, and healthcare, are strengthening India's role in the global life sciences landscape. Currently, there are over 95 life sciences GCCs in India, employing approximately 280,000 professionals. By 2030, this number is projected to reach 160 GCCs and around 420,000 employees. Advancements in artificial intelligence AI) are central to this transformation, driving innovation across drug discovery and clinical research. India's life sciences GCCs have evolved from operational support centres to world-class R&D engines, leveraging India’s robust talent pool, advanced technology adoption, and cost advantages. These GCCs are driving the future of Al-powered drug discovery and clinical research. Let’s explore further.

time-read
4 mins  |
BioSpectrum Indian Feb 2025